|
Age (year): mean (S.D.)
|
11.8 (2.0)
|
13.8 (2.4)
|
Z = −3.79
|
<0.001
|
|
Gender (male)
|
9 (18.0%)
|
12 (29.3%)
|
χ2(1) = 1.04
|
0.31
|
|
JIA subtype:
| | |
χ2(6) = 13.0
|
0.04
|
|
Systemic arthritis
|
5 (10.0%)
|
9 (22.0%)
| | |
|
Oligoarthritis persistent
|
11 (22.0%)
|
1 (2.4%)
| | |
|
Oligoarthritis extended
|
9 (18.0%)
|
9 (22.0%)
| | |
|
Polyarthritis (RF-negative)
|
22 (44.0%)
|
17 (41.5%)
| | |
|
Polyarthritis (RF-positive)
|
0 (0.0%)
|
1 (2.4%)
| | |
|
Psoriatic arthritis
|
1 (2.0%)
|
2 (4.9%)
| | |
|
Enthesitis-related arthritis
|
0 (0.0%)
|
2 (4.9%)
| | |
|
Data on subtype n.a.
|
2 (4.0%)
| | | |
|
Disease duration (year): mean (S.D.)a
|
5.2 (3.6)
|
8.0 (3.6)
|
Z = −3.23
|
0.001
|
|
Current use of medication:
| | | | |
|
NSAID use:
|
41 (82.0%)
|
17 (41.5%)
|
χ2(1) = 14.31
|
<0.001
|
|
Use of other analgesics:
|
10 (20.0%)
|
15 (36.6%)
|
χ2(1) = 2.33
|
0.13
|
|
Methotrexate use:
|
18 (36.0%)
|
17 (41.5%)
|
χ2(1) = 0.10
|
0.75
|
|
Anti-TNF agents use:
| | | | |
|
Etanercept
| |
31 (75.6%)
| | |
|
Adalimumbab
| |
3 (7.3%)
| | |
|
Infliximab
| |
3 (7.3%)
| | |
|
Treatment time with anti-TNF agents (year)
| |
2.4 (1.8)
| | |
